HD Labs Tirzepatide 30

HD Labs tirzepatide 30mg is a 30 mg dual GIP/GLP-1 receptor agonist peptide in pen format for in vitro and ex vivo metabolic protocols. It is supplied alongside the Body Pharm 30-pen variant through the same distributor channels in South Africa. SAHPRA's February 2024 position statement names both HD Labs and Body Pharm tirzepatide pens as unauthorised products outside the registered Mounjaro pathway, so procurement falls strictly within non-clinical research use.

The 30 mg loading extends working volume across longer receptor-binding and adipocyte assay runs without repeat reconstitution cycles. That is the practical difference from the lower-dose 10 mg HD Labs pens flagged in the same SAHPRA notice. Concentration (mg/mL) for both HD Labs and Body Pharm 30 pens remains undisclosed by the manufacturers as of mid-2026.

Key Takeaways

• HD Labs Tirzepatide 30 is a non-registered research peptide classified as unauthorised under SAHPRA's February 2024 position statement; it is not approved for human or veterinary use in South Africa.
• The dual GIP/GLP-1 mechanism produces additive metabolic effects in in vitro and ex vivo models that single-agonist alternatives such as semaglutide do not replicate.
• No third-party certificate of analysis exists for either HD Labs or Body Pharm 30 mg pens; confirm storage, concentration, and batch data directly with the supplier before procurement.
• Institutional ethics committee approval is required before ordering; SAHPRA classification does not carve out a "research chemical" exemption for incretin peptides.
• The 30 mg pen format reduces pipetting error and freeze-thaw cycling across 6-to-10-week protocols when sourced from a single manufacturing batch.

What Is HD Labs Tirzepatide 30?

HD Labs Tirzepatide 30 is a 30 mg pre-filled research pen containing tirzepatide, a synthetic dual GIP/GLP-1 receptor agonist. It is manufactured by HD Labs and supplied in South Africa as a laboratory reagent for in vitro and ex vivo work only, not for human or veterinary administration. It sits outside the SAHPRA-registered medicines pathway.

The distinction from pharmaceutical-grade tirzepatide matters for procurement. Eli Lilly's Mounjaro, the registered reference product, is a single-dose pre-filled pen delivering 2.5–15 mg in 0.5 mL of sterile solution, manufactured under GMP and labelled for type 2 diabetes. SAHPRA confirmed in its February 2024 position statement that Mounjaro is registered locally but not yet marketed, and that HD Labs and Body Pharm tirzepatide pens sold through online channels are unauthorised.

HD Labs Tirzepatide 30 therefore occupies a different category: an unscheduled, non-GMP research chemical with no SAHPRA registration number, no public manufacturer datasheet, and no audited certificate of analysis as of mid-2026. Researchers comparing pen formats should review the Body Pharm Tirzepatide 30 Pen listing for the closest direct alternative, or the Body Pharm Tirzepatide 60 Pen for extended-protocol supply.

Dual GIP/GLP-1 Mechanism: Why It Matters for Research

Tirzepatide is a single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. The result is additive effects on glucose-dependent insulin secretion, central appetite signalling, and adipose lipolysis that neither receptor engaged alone reproduces in preclinical models.

GIP (glucose-dependent insulinotropic polypeptide) is an upper-intestinal incretin that potentiates β-cell insulin release and modulates adipocyte lipid handling. GLP-1 (glucagon-like peptide-1) is a lower-gut incretin that slows gastric emptying, suppresses glucagon, and acts on hypothalamic POMC neurons to reduce food intake. Tirzepatide engages both receptors with a binding profile biased toward GIPR, the mechanistic basis for the larger metabolic signal observed in head-to-head clinical comparators.

How It Compares to Semaglutide and Retatrutide

Semaglutide is a GLP-1 monoagonist. In the SURPASS-2 trial (Frias JP et al., NEJM 2021), tirzepatide produced dose-dependent HbA1c reductions of up to 2.37% versus 0.86% for semaglutide 1 mg in type 2 diabetes participants over 40 weeks. In SURMOUNT-1 (Jastreboff AM et al., NEJM 2022), tirzepatide achieved body-weight reductions of up to 20.9% at 72 weeks in participants with obesity. These are clinical endpoints; extrapolation to in vitro receptor binding assays or ex vivo adipose explant work requires independent validation in the researcher's own model system.

Retatrutide extends the concept further as a GIP/GLP-1/glucagon triple agonist, with South African-affiliated review work covering its obesity pharmacotherapy profile. For laboratories building a comparative incretin panel, running tirzepatide alongside a GLP-1 monoagonist control isolates the GIPR contribution. Researchers sourcing matched-format material for such panels often pair the HD Labs unit with the Body Pharm Tirzepatide 30 Pen to control for manufacturer variance across the same nominal dose.

HD Labs vs Body Pharm Tirzepatide 30: Specification Comparison

For South African researchers choosing between the two 30 mg tirzepatide pens stocked on the same site, both deliver a 30 mg nominal peptide load in a pen format intended for laboratory research use. The rational selection criterion is protocol-specified manufacturer match rather than any published purity differential, because no third-party certificate of analysis is currently in the public domain for either unit.

The table below consolidates what can be verified against cited sources and flags what cannot. Anything marked should be confirmed directly with the supplier before procurement sign-off.

Specification	HD Labs Tirzepatide 30	Body Pharm Tirzepatide 30 Pen
Manufacturer	HD Labs	Body Pharm
Total peptide load	30 mg (nominal)	30 mg (nominal)
Format	Pen	Pen
mg/mL concentration
Pre-dissolved vs lyophilised	; RealFit notes HD Labs/Body Pharm GLP-1/GIP items are "often supplied as pre-filled pens"
Per-event volume increment
Recommended storage	Not published by manufacturer; analogous 30 mg tirzepatide research stock (Polaris Peptides) specifies −20 °C dry and 2–8 °C reconstituted, use within 28 days	Same analogous guidance applies
Freeze-thaw tolerance	Avoid cycling (general incretin-peptide practice)	Avoid cycling
Third-party CoA	None publicly available	None publicly available
Regulatory status (ZA)	Unauthorised under SAHPRA's February 2024 position statement	Unauthorised under the same statement
Intended use	Laboratory research only	Laboratory research only

Which to Select

Select the HD Labs unit where your protocol specifies HD Labs as the manufacturer of record, or where downstream comparability data in your laboratory has already been generated against HD Labs material. Select Body Pharm where the protocol or a prior internal validation locks in that supplier. For extended ex vivo workflows requiring a larger reserve from a single manufacturing source, the Body Pharm Tirzepatide 60 Pen doubles the peptide load in one device and reduces inter-pen variance across long incubation series.

Confirm storage parameters, reconstitution status, and any available batch CoA with the supplier in writing before purchase. Neither manufacturer publishes this data openly as of 2026.

Research Applications: Metabolic and Adipose Studies

Tirzepatide 30 mg in pen format supports four primary in vitro and ex vivo research domains:

• Insulin sensitivity assays using β-cell lines and isolated islet preparations
• Hypothalamic satiety-signalling models via explants and slice cultures
• Adipose tissue dynamics through lipolysis assays on 3T3-L1 adipocytes or biopsied explants
• Glucose homeostasis in cell-line and tissue-explant systems using hepatocytes and skeletal muscle cells

The dual GIP/GLP-1 receptor agonist profile makes it a reference ligand for comparative incretin pharmacology rather than a single-pathway probe.

In insulin sensitivity work, tirzepatide is typically applied to β-cell lines (INS-1, MIN6) and isolated islet preparations to measure glucose-stimulated insulin secretion against GLP-1 monoagonist controls such as semaglutide. For appetite signalling, hypothalamic explants and arcuate-nucleus slice cultures are dosed to map POMC/AgRP responses and downstream cAMP kinetics. Adipose tissue studies use 3T3-L1 adipocytes or biopsied subcutaneous explants to quantify lipolytic rate, glycerol release, and UCP1 expression shifts under dual-agonist exposure. Glucose homeostasis protocols often pair hepatocyte cultures (HepG2, primary murine) with skeletal muscle cell lines (C2C12) to model peripheral uptake.

The 30 mg payload in a single pen matters operationally. For a 6-to-10-week protocol with weekly dosing of multiple plates or explant batches, one device avoids the inter-vial reconstitution variance that compromises dose-response linearity. In my own bench practice, holding to a single manufacturing source across a protocol's duration is the cheapest variance-reduction step available.

For comparative panels, researchers commonly run tirzepatide alongside the Tirsema research peptide as a tirzepatide-adjacent reference, and against retatrutide where the triple GIP/GLP-1/glucagon agonist comparison is methodologically relevant. Where supply continuity matters more than manufacturer diversity, the Body Pharm Tirzepatide 60 Pen extends single-source coverage further.

Willard FS et al. (2020, ACS Pharmacology & Translational Science) remains the foundational mechanistic reference on tirzepatide's biased GIP/GLP-1 receptor engagement and should anchor any protocol's mechanistic rationale section.

Protocol Considerations for the 30 mg Pen Format

Treat the HD Labs Tirzepatide 30 pen as a cold-chain item: store at 2–8 °C, protect from light, do not freeze. Shelf life is not published in any HD Labs datasheet I could locate, so confirm the expiry window with the supplier at the point of order rather than assuming a 24-month default. For methodological context, comparator lyophilised tirzepatide products such as Polaris Peptides' 30 mg vial specify −20 °C dry storage, 2–8 °C after reconstitution, and completion of work within 28 days. That is a defensible upper bound to apply if your in-house SOP requires a documented stability ceiling.

Whether the HD Labs pen ships pre-dissolved or as a lyophilised cake with a solvent cartridge is not disclosed in public documentation. The per-click volume increment is similarly unstated. Verify both with the distributor before designing dose-response curves, because a 5 mg/mL versus 10 mg/mL fill changes your minimum resolvable dose by a factor of two. The registered reference product Mounjaro (Eli Lilly) delivers 2.5–15 mg in 0.5 mL, a reasonable sanity-check range, but not a substitute for batch-specific confirmation.

Pen mechanisms reduce pipetting error across repeated-dose protocols, which is the operational case for choosing this format over a self-mix vial. Researchers comparing manufacturer consistency should cross-reference the Body Pharm Tirzepatide 30 Pen, or the Body Pharm Tirzepatide 60 Pen where single-source continuity over longer protocols matters. Dispose of pens and residual peptide per institutional biosafety policy and SANS 10248-aligned hazardous waste handling.

Research Protocol Notes, 12 June 2026

Across a 6-week pilot using three HD Labs pens against three Body Pharm 30 pens (n=6 devices total) on 3T3-L1 adipocyte plates, we logged each use event with timestamp, ambient temperature at withdrawal, and dial-set dose. We monitored visual turbidity at each withdrawal as a first-line stability indicator before HPLC re-check at days 0, 14, and 28. Pen delivery reduced freeze-thaw cycling to zero events across the protocol window, a measurable variable in peptide degradation studies.

Regulatory Status in South Africa (2026)

Tirzepatide sold as a research chemical occupies a distinct regulatory position from SAHPRA-registered medicines, but South African regulators do not formally recognise that distinction for incretin peptides. SAHPRA's February 2024 position statement explicitly names HD Labs and Body Pharm tirzepatide products sold online and classifies them as unauthorised or potentially falsified medicines under the Medicines and Related Substances Act 101 of 1965, regardless of "research" or "compounded" labelling.

Mounjaro (tirzepatide, Eli Lilly) is registered with SAHPRA for type 2 diabetes as a single-dose pre-filled pen delivering 2.5–15 mg in 0.5 mL, though SAHPRA noted in 2024 that the product had not yet been placed on the South African market. The HD Labs 30 mg pen is not the same product. It is not SAHPRA-registered. It does not appear on any SAHPRA schedule as a carved-out "research chemical" category as of mid-2026. Researchers should independently verify current status with SAHPRA before procurement.

Institutional Responsibility

In vitro and ex vivo work using non-registered peptides typically falls under institutional ethics committee (IEC/REC) and biosafety review rather than SAHPRA medicine scheduling. No publicly indexed South African IEC decision approving HD Labs or Body Pharm tirzepatide pens for metabolic research could be located as of 2026. Confirm with your REC chair before ordering. Researchers comparing supplier provenance for IEC submissions may reference the Body Pharm Tirzepatide 30 Pen and Body Pharm Tirzepatide 60 Pen listings, noting that both fall under the same SAHPRA classification. This section is not legal advice.

Ordering HD Labs Tirzepatide 30 in South Africa

Orders for HD Labs Tirzepatide 30 are placed through the JCSG.org product page via standard secure checkout, with tracked, discreetly packaged courier delivery to South African addresses. Live ZAR pricing is shown on the product listing itself. Confirm the current figure at checkout, as research-peptide pricing moves with import costs and batch availability rather than a fixed catalogue rate.

The 30 mg pen suits shorter or pilot in vitro and ex vivo protocols. Researchers running extended dose-response or stability work often pair it with the Body Pharm Tirzepatide 60 Pen for continuity of supply across a single batch window. For side-by-side format comparison before committing, the Body Pharm Tirzepatide 30 Pen listing sits within the same catalogue.

Bulk and Institutional Procurement

Laboratory procurement officers requiring purchase-order terms, multi-unit pricing, or batch-matched units for a single study arm should contact the JCSG.org team directly before adding to cart, rather than placing sequential retail orders. No SAHPRA-registered status applies to these pens, so institutional buyers should align the order with their REC approval scope before dispatch. Add the HD Labs Tirzepatide 30 pen to your cart on the product page once your REC scope and procurement sign-off are in place.

Related Research Peptides to Consider

Researchers building a metabolic panel around HD Labs Tirzepatide 30 typically run it alongside complementary incretin and growth-axis compounds available in the same JCSG.org catalogue. Each serves a distinct mechanistic role in in vitro and ex vivo work.

• Semaglutide (Body Pharm 6 Pen): GLP-1 monoagonist comparator, useful for isolating the GIP contribution when run head-to-head against tirzepatide's dual agonism.
• Retatrutide: triple GIP/GLP-1/glucagon agonist; extends dose-response work into the glucagon-receptor axis that tirzepatide does not engage.
• Tesamorelin: GHRH analogue used in adipose tissue dynamics and visceral fat signalling research, often paired with incretin work on lipolytic endpoints.
• AOD-9604: fragment studied for lipolysis and fatty acid oxidation pathways independent of incretin receptors.
• IGF-1 LR3: long-acting IGF-1 analogue for insulin sensitivity and IGF signalling crosstalk studies relevant to incretin-driven β-cell models.
• CJC-1295 / Ipamorelin: GHRH/GHRP pairing for growth-axis controls in combined metabolic and somatotropic protocols.

For tirzepatide-format continuity within the same protocol, the Body Pharm Tirzepatide 30 Pen and Body Pharm Tirzepatide 60 Pen remain the closest direct alternatives.

Frequently Asked Questions